12/17
04:00 pm
iva
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16
02:30 am
iva
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Low
Report
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
12/12
04:00 pm
iva
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
Low
Report
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
11/22
10:19 am
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at Stifel Nicolaus from $20.00 to $17.00. They now have a "buy" rating on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at Stifel Nicolaus from $20.00 to $17.00. They now have a "buy" rating on the stock.
11/21
04:00 pm
iva
Inventiva reports 2024 Third Quarter Financial Information¹
Low
Report
Inventiva reports 2024 Third Quarter Financial Information¹
11/20
04:00 pm
iva
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Low
Report
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
11/15
04:00 pm
iva
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Low
Report
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
11/12
08:19 am
iva
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
10/30
04:00 pm
iva
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Medium
Report
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
10/21
08:30 am
iva
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Low
Report
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
10/15
01:32 pm
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
10/14
01:45 pm
iva
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Medium
Report
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
10/14
02:35 am
iva
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
High
Report
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
10/14
02:30 am
iva
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
High
Report
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study